Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
Home Headlines Britain gives first European approval to Valneva COVID shot
Headlines

Britain gives first European approval to Valneva COVID shot

by jcp April 14, 2022
April 14, 2022
gawdo

By Natalie Grover and Sarah Morland

LONDON/PARIS (Reuters) -Britain approved Valneva’s COVID-19 vaccine on Thursday, becoming the first European country to clear the use of the French firm’s shot in a move that boosted its shares by more than 20%.

The go-ahead is the sixth COVID vaccine approval by Britain and comes even though London last September scrapped a 1.4 billion euro ($1.5 billion) deal to buy the Valneva shot, alleging the company was in breach of its obligations under the agreement – which Valneva denied.

The company said it was in discussions to supply up to 25,000 doses to the UK’s National Health Service and frontline workers in Scotland. It said talks over a settlement following the UK government’s decision to ditch its contract continued.

Announcing the approval, the UK’s Medicines and Healthcare Products Regulatory Agency (MRHA) said it was the first, whole-virus inactivated COVID-19 vaccine to gain approval in the UK, adding the shot met safety, quality and effectiveness standards.

However demand prospects could be limited in the UK given the vaccination rate is already relatively high, with about 73% of the population having had two doses and almost 60% having had a booster. The government is also rolling out fourth doses to the vulnerable and the elderly.

“The UK continues to have sufficient supply for its vaccination programme,” a Department of Health and Social Care spokesperson said.

Still, the regulatory nod is a boost for the company as the European Medicines Agency (EMA) assesses the vaccine for possible approval. The European Commission has signed an advance deal for up to 60 million doses.

ADDITIONAL AUTHORIZATIONS

Valneva’s stock jumped more than 20% to their highest since Jan. 5, helping recover ground lost so far this year amid uncertainty about the regulatory approval process.

“We believe that this new approval could … lead to additional marketing authorizations in other regions of the world,” Valneva chief Thomas Lingelbach said in a statement.

The vaccine is seen to have two main advantages – it can be stored at similar temperatures to those in a domestic fridge, and it relies on technology that has been used for decades, for instance in some shots against polio, influenza and hepatitis A.

The approach involves growing the virus in a lab, then rendering it completely inactive so it cannot infect cells or replicate in the body, but can still trigger an immune response.

It is seen by some as having the potential to win over people wary of some vaccines which use mRNA technology.

Rx Securities’ managing director Samir Devani said even after the mass roll-out, Valneva’s vaccine could still be useful if a new variant arises.

“The fact that it is available on hand is good news, although the exact revenue profile beyond the orders already received from the EU and Bahrain remains unclear,” he said.

Valneva said in March it expected a positive EMA recommendation this month and had begun manufacturing. It said it has inventory ready for labelling and deployment once it is approved there.

Bahrain granted Valneva’s vaccine emergency use authorisation in early March.

Earlier this year, the company said early data suggested three doses of its vaccine neutralised the Omicron variant of the virus.

($1 = 0.9198 euros)

(Reporting by Aby Jose Koilparambil in Bengaluru, with Benoit Van Overstraeten and Sarah Morland in Paris and Natalie Grover in London; Editing by Josephine Mason and David Holmes)

www.gawdo.com
Share on FacebookShare on TwitterShare on Linkedin
0 FacebookTwitterPinterestEmail
previous post
Elon Musk targets Twitter with $41 billion cash takeover offer
next post
A new loan scheme: Will the SME sector finally get the security it needs?

You may also like

Finland, Sweden to send teams to Turkey to...

May 24, 2022

Germany’s vaccine panel says one COVID shot enough...

May 24, 2022

EU calls for Russia dialogue to unlock Ukraine...

May 24, 2022
Editorial & Advertiser disclosureEditorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gawdo.com
https://www.gawdo.com
  • About us
  • Advertising & Terms of Use
  • Contact Us
  • Privacy Policy

@2021 - All Right Reserved.


Back To Top
Startup Observer.com
  • Home
  • Industries
  • Innovation
  • outsourcing
  • Business
  • Finance
  • Headlines
  • Opinion
  • News
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT